Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MYGN Stock Forecast 2026-2027
$6.11
Current Price
$569.54M
Market Cap
Buy 3
Hold 7
Sell 2
Wall St Analyst Ratings
Distance to MYGN Price Targets
+194.6%
To High Target of $18.00
+30.9%
To Median Target of $8.00
-34.5%
To Low Target of $4.00
MYGN Price Momentum
-6.9%
1 Week Change
-12.6%
1 Month Change
-53.5%
1 Year Change
-0.7%
Year-to-Date Change
-60.5%
From 52W High of $15.47
+62.5%
From 52W Low of $3.76
📊 TOP ANALYST CALLS
Did MYGN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Myriad Genetics is one of their latest high-conviction picks.
Latest MYGN Stock Price Targets & Analyst Predictions
Based on our analysis of 23 Wall Street analysts, MYGN has a neutral consensus with a median price target of $8.00 (ranging from $4.00 to $18.00). The overall analyst rating is Buy (6.2/10). Currently trading at $6.11, the median forecast implies a 30.9% upside. This outlook is supported by 3 Buy, 7 Hold, and 2 Sell ratings.
The most optimistic forecast comes from Matthew Sykes at Goldman Sachs, projecting a 194.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MYGN Analyst Ratings
3
Buy
7
Hold
2
Sell
MYGN Price Target Range
Low
$4.00
Average
$8.00
High
$18.00
Current: $6.11
Latest MYGN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MYGN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 11, 2025 | Piper Sandler | Dave Weiner | Overweight | Maintains | $8.50 |
| Nov 5, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $6.50 |
| Nov 4, 2025 | TD Cowen | Dan Brennan | Hold | Maintains | $9.00 |
| Nov 4, 2025 | UBS | Lu Li | Neutral | Maintains | $8.00 |
| May 21, 2025 | Scotiabank | Sung Ji Nam | Sector Perform | Downgrade | $6.00 |
| May 15, 2025 | Piper Sandler | Dave Weiner | Overweight | Maintains | $9.00 |
| May 8, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Downgrade | $6.00 |
| May 7, 2025 | Raymond James | Andrew Cooper | Outperform | Reiterates | $10.00 |
| May 7, 2025 | UBS | Lu Li | Neutral | Maintains | $7.00 |
| May 7, 2025 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $8.00 |
| Apr 17, 2025 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $14.00 |
| Apr 9, 2025 | Guggenheim | Subbu Nambi | Neutral | Downgrade | $N/A |
| Apr 1, 2025 | Scotiabank | Sung Ji Nam | Sector Outperform | Maintains | $20.00 |
| Mar 12, 2025 | Piper Sandler | Dave Weiner | Overweight | Upgrade | $12.50 |
| Mar 4, 2025 | Piper Sandler | Dave Weiner | Neutral | Maintains | $11.50 |
| Mar 3, 2025 | B of A Securities | Derik De Bruin | Underperform | Maintains | $11.00 |
| Feb 25, 2025 | UBS | Lu Li | Neutral | Maintains | $16.00 |
| Feb 25, 2025 | Raymond James | Andrew Cooper | Outperform | Reiterates | $19.00 |
| Feb 12, 2025 | Craig-Hallum | John Wilkin | Buy | Initiates | $29.00 |
| Jan 30, 2025 | Piper Sandler | John Peterson | Neutral | Maintains | $14.00 |
Myriad Genetics Inc. (MYGN) Competitors
The following stocks are similar to Myriad Genetics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Myriad Genetics Inc. (MYGN) Financial Data
Myriad Genetics Inc. has a market capitalization of $569.54M with a P/E ratio of -4.3x. The company generates $825.30M in trailing twelve-month revenue with a -48.5% profit margin.
Revenue growth is -3.6% quarter-over-quarter, while maintaining an operating margin of -11.3% and return on equity of -72.5%.
Valuation Metrics
Market Cap
$569.54M
Enterprise Value
$644.83M
P/E Ratio
-4.3x
PEG Ratio
-0.2x
Price/Sales
0.7x
Growth & Margins
Revenue Growth (YoY)
-3.6%
Gross Margin
+69.9%
Operating Margin
-11.3%
Net Margin
-48.5%
EPS Growth
-3.6%
Financial Health
Cash/Price Ratio
+25.5%
Current Ratio
2.3x
Debt/Equity
56.9x
ROE
-72.5%
ROA
-5.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Myriad Genetics Inc. (MYGN) Business Model
About Myriad Genetics Inc.
What They Do
Biotechnology company specializing in genetic tests.
Business Model
Myriad Genetics generates revenue by developing and commercializing genetic tests that assess the risk of cancer and hereditary conditions. Their tests are utilized by healthcare providers to inform patient care and treatment decisions, thereby creating a demand for their innovative diagnostic solutions.
Additional Information
The company is a leader in molecular diagnostics, focusing on personalized medicine and contributing to advancements in understanding genetic contributions to diseases. Their comprehensive testing portfolio aids oncologists, genetic counselors, and researchers, making Myriad Genetics a critical player in the healthcare and medical research sectors.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
2,700
CEO
Mr. Samraat S. Raha
Country
United States
IPO Year
1995
Website
www.myriad.comMyriad Genetics Inc. (MYGN) Latest News & Analysis
Latest News
Quick Summary
Myriad reported preliminary unaudited results for Q4 and full year 2025 and has issued financial guidance for 2026.
Why It Matters
Myriad's preliminary results and 2026 financial guidance signal its performance trajectory, influencing investor sentiment and future stock valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Myriad Genetics, Inc. (NASDAQ: MYGN) CEO Sam Raha will present at the J.P. Morgan Healthcare Conference on Jan. 14 at 5:15 pm PT.
Why It Matters
Myriad Genetics' CEO presentation at a major healthcare conference may influence investor sentiment and stock performance by showcasing company strategies and innovations in diagnostics.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
MYGN is expected to grow due to new genetic tests and a revised CCC strategy, though it faces revenue challenges from the loss of GeneSight coverage.
Why It Matters
MYGN's growth potential from new tests could boost future revenue, but the loss of GeneSight coverage may hinder short-term financial performance, impacting stock valuation.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Myriad (MYGN) recently reported earnings, and investors are looking ahead to upcoming developments for the stock.
Why It Matters
Earnings reports influence stock performance; upcoming developments can impact investor sentiment and stock valuation, affecting trading strategies and potential returns.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Clairity, Myriad Genetics, and MagView have collaborated to enhance breast cancer risk assessment for women, aiming to identify those at high risk without adding administrative burdens.
Why It Matters
The collaboration aims to enhance breast cancer risk assessment, potentially increasing Myriad Genetics' market position and driving demand for its genetic testing services, impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Myriad Genetics (NASDAQ: MYGN) will participate in the Wolfe Research Healthcare Conference on Nov. 18, 2025, featuring a fireside chat at 1:20 pm ET.
Why It Matters
Myriad Genetics' participation in prominent healthcare conferences can signal strategic growth and innovation, potentially influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MYGN Stock
What is Myriad Genetics Inc.'s (MYGN) stock forecast for 2026?
Based on our analysis of 23 Wall Street analysts, Myriad Genetics Inc. (MYGN) has a median price target of $8.00. The highest price target is $18.00 and the lowest is $4.00.
Is MYGN stock a good investment in 2026?
According to current analyst ratings, MYGN has 3 Buy ratings, 7 Hold ratings, and 2 Sell ratings. The stock is currently trading at $6.11. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MYGN stock?
Wall Street analysts predict MYGN stock could reach $8.00 in the next 12 months. This represents a 30.9% increase from the current price of $6.11. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Myriad Genetics Inc.'s business model?
Myriad Genetics generates revenue by developing and commercializing genetic tests that assess the risk of cancer and hereditary conditions. Their tests are utilized by healthcare providers to inform patient care and treatment decisions, thereby creating a demand for their innovative diagnostic solutions.
What is the highest forecasted price for MYGN Myriad Genetics Inc.?
The highest price target for MYGN is $18.00 from Matthew Sykes at Goldman Sachs, which represents a 194.6% increase from the current price of $6.11.
What is the lowest forecasted price for MYGN Myriad Genetics Inc.?
The lowest price target for MYGN is $4.00 from at , which represents a -34.5% decrease from the current price of $6.11.
What is the overall MYGN consensus from analysts for Myriad Genetics Inc.?
The overall analyst consensus for MYGN is neutral. Out of 23 Wall Street analysts, 3 rate it as Buy, 7 as Hold, and 2 as Sell, with a median price target of $8.00.
How accurate are MYGN stock price projections?
Stock price projections, including those for Myriad Genetics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 3:42 AM UTC